











25. MCCAULEY J, FUNG J, JAIN A, TODO S, STARZL TE. The effects of FK506 on renal function after liver transplantation. *Transpl Proc* 1990; 22: 17.
26. VENKATARAMANAN R, JAIN A, WARTY VS, et al. Pharmacokinetics of FK506 in transplant patients. *Transpl Proc* 1991; 23: 2736.
27. PRASAD TNV, STIFF DD, SUBBOTINA N, et al. FK506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. *Res Commun Chem Pathol Pharmacol* 1994; 84: 35.
28. IWASAKI K, MATSUDA H, NAGASE K, SHIRAGA T, TOKUMA Y, UCHIDA K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. *Res Commun Chem Pathol Pharmacol* 1993; 82: 209.
29. JENSEN C, JORDAN M, SHAPIRO R, et al. Interaction between tacrolimus and erythromycin. *Lancet* 1994; 344: 825.
30. FUNG JJ, ALESSIANI M, ABU-ELMAGD K, et al. Adverse effects associated with the use of FK506. *Transpl Proc* 1991; 23: 3105.
31. REDING R, WALLEMACQ PE, LAMY ME, et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. *Transplantation* 1994; 57: 93.
32. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. *N Engl J Med* 1994; 331: 1110.
33. JINDAL RM. Posttransplant diabetes mellitus-A review. *Transplantation* 1994; 58: 1289.
34. SCANTLEBURY V, SHAPIRO R, FUNG J, et al. New onset of diabetes in FK506 vs. cyclosporine-treated kidney transplant recipients. *Transpl Proc* 1991; 23: 3169.
35. ROTH D, MILGROM M, ESQUENAZI V, FULLER L, BURKE G, MILLER JS. Post-transplant hyperglycemia. *Transplantation* 1989; 47: 278.